Genmab A (GMAB) Current Deferred Revenue (2020 - 2026)

Genmab A has reported Current Deferred Revenue for 5 years, with the latest figure at -$7.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 110.0% year-over-year to -$7.0 million; the trailing twelve-month figure through Mar 2026 stood at -$7.0 million (down 110.0% YoY), and the FY2025 full-year result was $95.0 million, up 3066.67% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at -$7.0 million, down from $95.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $95.0 million in Q4 2025, with the low at -$7.0 million in Q1 2026.
• Historically, Current Deferred Revenue has averaged $42.9 million across 4 years, with a median of $67.0 million in 2025.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue soared 3066.67% — and 2026, when it slumped 110.0%.
• Genmab A's Current Deferred Revenue stood at $5.0 million in 2023, then sank by 40.0% to $3.0 million in 2024, then soared by 3066.67% to $95.0 million in 2025, then slumped by 107.37% to -$7.0 million in 2026.
• The last three Current Deferred Revenue figures came in at -$7.0 million (Q1 2026), $95.0 million (Q4 2025), and $67.0 million (Q3 2025), per Business Quant data.